All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 27, 2023
Home » Topics » Inflammatory, BioWorld Science

Inflammatory, BioWorld Science
Inflammatory, BioWorld Science RSS Feed RSS

Microscopic image of cytoskeletons.
Inflammatory

Cytoskeletal deformations raise antiviral alarm

Sep. 19, 2022
By Anette Breindl
No Comments
Pathogen-associated molecular patterns (PAMPs) are by themselves not enough to set off a full innate immune response to viral infection. Instead, structural changes to the actin cytoskeleton primed the activation of RIG-I-like receptors (RLRs), a family of intracellular RNA sensors that detect many types of viral RNA. When primed RLRs then encountered viral RNA, they set off an innate immune response that led to the production of interferons.
Read More
Scientist, microscope and dropper
Inflammatory

Delivery of engineered Tregs with tunable IL-2 signaling support enhances Treg potency and survival

Sep. 15, 2022
No Comments
Gentibio Inc. has announced preclinical data relating to the company's platform technology, demonstrating technical progress to engineer regulatory T cells (Tregs) for the prevention and treatment of autoimmune diseases.
Read More
Musculoskeletal

Domainex nominates DMXD-011 as preclinical drug candidate for interferonopathies

Sep. 15, 2022
No Comments
Following a research program to identify inhibitors of protein kinases TBK1 and IKK-ε, Domainex Ltd. has nominated DMXD-011 as a preclinical drug candidate.
Read More
ESMO 2022

Study gives new insights into pollution, inflammation, cancer initiation

Sep. 12, 2022
By Anette Breindl
No Comments
“The association between air pollution and lung cancer is not new,” Charles Swanton told the audience at the European Society of Medical Oncology (ESMO) 2022 Congress. But as with so many associations, causation has been hard to establish, partly due to the puzzling absence of mutations.
Read More
Inflammatory

New NLRP3 inflammasome inhibitors identified at Hangzhou Innogate Pharma

Sep. 8, 2022
No Comments
Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders.
Read More
Acquisition target
Dermatologic

Arcutis set to acquire Ducentis BioTherapeutics

Sep. 8, 2022
No Comments
Arcutis Biotherapeutics Inc. has entered into an agreement to acquire Ducentis Biotherapeutics Inc., a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.
Read More
Vial and syringe
Inflammatory

Early treatment with short doses of rapamycin extends lifespan later on

Sep. 8, 2022
By Mar de Miguel
No Comments
A brief pulse of rapamycin before the onset of aging extended lifespan by triggering lasting increases in autophagy. The authors called this phenomenon "rapamycin memory." Elevated autophagy was accompanied by increased levels of LManV and lysozyme in fruit flies, in intestinal enterocytes in female fly models, and its Man2B1 homologue in mice. In mice, a 3-month treatment in early adulthood had the same effect as chronic treatment, even 6 months after rapamycin was withdrawn. In the study published in the Aug. 29, 2022, issue of Nature Aging and led by researchers at the Max Planck Institute, scientists showed that the lifespan-increasing response to rapamycin treatment decreased with the age at which treatment is started.
Read More
Inflammatory

Novel C3-targeting siRNA APL-3007 shows promising preclinical results in monkeys

Sep. 7, 2022
No Comments
Dysregulation of complement activation plays a key role in the pathophysiology of several diseases, which makes it an attractive therapeutic target. C3 has an important role and central position within the signaling cascade, and is a potential target for therapy.
Read More
Inflammatory

TQS-168 demonstrates geroprotective effects in mice

Aug. 30, 2022
No Comments
Tranquis Therapeutics Inc. has announced preclinical data on the antiaging effects of TQS-168, a small-molecule modulator of PGC-1alpha (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha).
Read More
Pill over molecule structures
ACS Fall 2022

Nimbus Therapeutics details discovery, discloses structure of selective TYK2 inhibitor NDI-034858

Aug. 30, 2022
No Comments
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 46 47 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 27, 2022.
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Elderly woman holding illustration of brain with missing puzzle piece

    ‘Not a slowdown, a reversal’: Truebinding tackling Alzheimer’s via galectin-3

    BioWorld
    In Alzheimer’s, the amyloid beta hypothesis has proved most persistent in terms of drug development efforts to date, but aggregation of other pathogenic factors –...
  • Livzon licenses GERD drug from Onconic in $127.5M deal

    BioWorld
    Livzon Pharmaceutical Group Inc. licensed rights to zastaprazan, a gastroesophageal reflux disease (GERD) treatment candidate, from Onconic Therapeutics Inc. in a...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing